Anzeige
Meldung des Tages: Von KI-Energie bis Waste-to-Energy: Global Power erweitert seine Position im globalen Infrastrukturmarkt

MoonLake News

Aktie
WKN:  A3DFA7 ISIN:  KY61559X1045 US-Symbol:  MLTX Branche:  Biotechnologie Land:  Schweiz
17,52 $
-0,37 $
-2,07%
14,933 € 18:49:27 Uhr
Depot/Watchlist
Marktkapitalisierung *
745,67 Mio. €
Streubesitz
28,79%
KGV
-28,65
Index-Zuordnung
-

MoonLake Immunotherapeutics News

08.12.25 - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
08.12.25 - PR Newswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX PR Newswire
07.12.25 - PR Newswire
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit PR Newswire
05.12.25 - PR Newswire
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for Investors - Contact Levi & Korsinsky PR Newswire
05.12.25 - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics PR Newswire
05.12.25 - PR Newswire
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman PR Newswire
04.12.25 - PR Newswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX PR Newswire
04.12.25 - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
03.12.25 - PR Newswire
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman PR Newswire
02.12.25 - PR Newswire
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit PR Newswire
02.12.25 - PR Newswire
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
02.12.25 - PR Newswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX PR Newswire
01.12.25 - PR Newswire
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority PR Newswire
01.12.25 - PR Newswire
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
01.12.25 - PR Newswire
The Gross Law Firm Reminds MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
The Gross Law Firm Reminds MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX PR ...
01.12.25 - PR Newswire
MoonLake Immunotherapeutics (NASDAQ: MLTX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
MoonLake Immunotherapeutics (NASDAQ: MLTX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit PR Newswire
01.12.25 - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
01.12.25 - PR Newswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX PR Newswire
30.11.25 - PR Newswire
Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX PR Newswire
28.11.25 - PR Newswire
MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman
MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman PR Newswire

Newssuche

Videos

newspaper
20.04.26 0,00%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »